Wernsman Young Neeva, Gashema Pierre, Giesbrecht David, Munyaneza Tharcisse, Maisha Felicien, Mwebembezi Fred, Budodo Rule, Leonetti Alec, Crudale Rebecca, Iradukunda Vincent, Jean Bosco Ntwari, Kirby Rebecca I, Boyce Ross M, Mandara Celine I, Kanyankole Grace K, Ntaro Moses, Okell Lucy C, Watson Oliver J, Mulogo Edgar, Ishengoma Deus S, Hangi Stan, Karema Corine, Mazarati Jean-Baptiste, Juliano Jonathan J, Bailey Jeffrey A
Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island.
Center for Computational and Molecular Biology, Brown University, Providence, Rhode Island.
J Infect Dis. 2025 Feb 4;231(1):269-280. doi: 10.1093/infdis/jiae475.
In Africa, the first Plasmodium falciparum artemisinin partial resistance mutation was Kelch13 (K13) 561H, detected and validated at appreciable frequency in Rwanda in 2014. Surveillance to better define the extent of the emergence in Rwanda and neighboring countries is critical.
We used novel liquid blood drop preservation with pooled sequencing to provide cost-effective rapid assessment of resistance mutation frequencies at multiple collection sites across Rwanda and neighboring regions in Uganda, Tanzania, and the Democratic Republic of the Congo. Malaria-positive samples (N = 5465) from 39 health facilities collected between May 2022 and March 2023 were sequenced in 199 pools.
In Rwanda, K13 561H and 675V were detected in 90% and 65% of sites, with an average frequency of 19.0% (range, 0%-54.5%) and 5.0% (0%-35.5%), respectively. In Tanzania, 561H had high frequency in multiple sites. 561H appeared at 1.6% in Uganda. 561H was absent from the Democratic Republic of the Congo, although 675V was seen at low frequency. Concerningly, candidate mutations were observed: 441L, 449A, and 469F co-occurred with validated mutations, suggesting that they are arising under the same pressures. Other markers for decreased susceptibility to artemether-lumefantrine are common: P falciparum multidrug resistance protein 1 N86 at 98.0% (range, 63.3%-100%) and 184F at 47.0% (0%-94.3%) and P falciparum chloroquine resistance transporter 76T at 14.7% (0%-58.6%). Additionally, sulfadoxine-pyrimethamine-associated mutations show high frequencies.
K13 mutations are rapidly expanding in the region, further endangering control efforts with the potential of engendering partner drug resistance.
在非洲,首个恶性疟原虫青蒿素部分抗性突变是凯尔奇13(K13)561H,于2014年在卢旺达被检测到并得到相当频率的验证。开展监测以更好地界定该突变在卢旺达及周边国家的出现程度至关重要。
我们采用新型液滴血保存及混合测序技术,以经济高效的方式快速评估卢旺达以及乌干达、坦桑尼亚和刚果民主共和国等周边地区多个采集点的抗性突变频率。对2022年5月至2023年3月期间从39个医疗机构采集的疟疾阳性样本(N = 5465)进行199个混合样本测序。
在卢旺达,90%的采集点检测到K13 561H,65%的采集点检测到K13 675V,平均频率分别为19.0%(范围0% - 54.5%)和5.0%(0% - 35.5%)。在坦桑尼亚,多个采集点561H频率较高。在乌干达,561H出现频率为1.6%。在刚果民主共和国未检测到561H,但675V出现频率较低。令人担忧的是,观察到了候选突变:441L、449A和469F与已验证的突变共同出现,表明它们是在相同压力下产生的。其他对蒿甲醚 - 本芴醇敏感性降低的标志物很常见:恶性疟原虫多药抗性蛋白1 N86出现频率为98.0%(范围63.3% - 100%),184F出现频率为47.0%(0% - 94.3%),恶性疟原虫氯喹抗性转运蛋白76T出现频率为14.7%(0% - 58.6%)。此外,与磺胺多辛 - 乙胺嘧啶相关的突变出现频率较高。
K13突变在该地区迅速扩散,进一步危及防控工作,可能导致对联合用药产生抗性。